US company started clinicl trial of Tissue Collection to ID TCRs From Renal Clear Cell Carcinoma Patients Responding to Immune Checkpoint Inhibitors

TScan Therapeutics, Inc is recruiting patients for the clinical trial of Tissue Collection to ID TCRs From Renal Clear Cell Carcinoma Patients Responding to Immune Checkpoint Inhibitors.

T Cell Receptor-engineered T-cell therapy (TCR T-cell therapy) offers a potentially transformative approach to treating cancer, but is currently limited by the lack of known targets. Arguably the most clinically meaningful way to discover new targets and TCRs for TCR T-cell therapy is to study the tumorinfiltrating lymphocytes of patients that are actively responding to immune checkpoint inhibitor (ICI) therapy. These T cells are clonally expanded as a result of checkpoint inhibition and are responsible for the patient's clinical response. The goal of this study is to acquire tumor and blood samples from up to 40 patients with renal cell carcinoma (RCC) malignancies who respond to ICI therapy. T cells will be isolated from these samples and the targets of their TCRs determined using TScan's genome-wide, high-throughput target ID technology. The expected outcome of this study is the discovery of a collection of new targets for TCR T-cell therapy, along with associated TCRs that will then be developed as novel therapies for patients with similar malignancies.

The clinical trail started on December 17, 2020. The indicative completion of the clinical trial will be expected in December 17, 2022.

Among primary outcome measures is the Single Cell Sequencing. Determine, through single-cell sequencing, the TCR repertoire of these tumor and blood samples to determine new targets.

There are a number of conditions that do not allow participation, such as:

• Concurrent disease or condition that would make the patient inappropriate for study participation, or any serious medical or psychiatric disorder that would interfere with the subject's safety.
• Dementia, altered mental status, or any psychiatric condition that would prohibit the understanding or rendering of informed consent.
• History of serious or life-threatening allergic reaction to local anesthetics (i.e., lidocaine, xylocaine).

The full list can be viewed at the link below.

The study will take place at the Washington University School of Medicine, Saint Louis, Missouri, United States.

The page dedicated to this clinical trial can be found here: https://ichgcp.net/clinical-trials-registry/NCT04680416